إدارة نزيف الأنف المتكرر في توسع الشعيرات النزفي الوراثي

Recurrent and often severe epistaxis is the most common manifestation of HHT, occurring in >90% of adults.

On the strength of several relatively small studies available at the time of the guidelines conference, systemic antiangiogenic therapy is now recommended as an option for managing epistaxis that has failed to respond to moisturizing topical therapies, oral tranexamic acid, and/or local procedural ablative therapies.

Risks and benefits of antiangiogenic medications should be considered, as well as alternatives, such as septodermoplasty and nasal closure, in these patients.